Across TCGA pan-cancer cohorts, RNASEK Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RNASEK data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher RNASEK Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNASEK expression acts as an unfavorable survival marker.

SARC are the cancer types where RNASEK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.086	0.611	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: RNASEK tumor-vs-normal RNA expression · all RNASEK data types